NYSE:UNH

UnitedHealth Group Inc (UNH)

395.62
-6.11 (1.52%)
as of Aug 17, 2026, 8:00:00 pm Market Open.
289 watching
0
Investor Insights
star iconAug 16, 2026, 12:00 am

This summary was created by AI, based on 36 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) has seen a tumultuous year, with many experts highlighting the volatility stemming from changes in leadership, regulatory pressures, and rising medical costs. Positive reviews point to regaining earnings power, especially with the return of the former CEO, who is expected to manage costs effectively and steer the company towards recovery. However, there are significant concerns about the impact of government regulations and Medicare adjustments, which could pressure margins and complicate growth prospects. The consensus reflects a blend of optimism for long-term recovery juxtaposed with caution due to ongoing industry challenges and political uncertainties. In summary, while there are indicators of potential upside, the unpredictable nature of healthcare reforms in the U.S. builds a case for cautious investment.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
Cvs, CVS
PAST TOP PICK
(A Top Pick Jun 24/21, Up 27%) Adding to it. Is American's largest healthcare insurer and healthcare services. This synergy is great for customers. Also, healthcare offers defense as well as growth. Chart is trending upwards as the market goes down.
PAST TOP PICK
(A Top Pick Oct 20/20, Up 52%) Great business. Dominant player in managed care. GARP. Executing exceptionally well, consistent.
COMMENT
It beat two weeks ago, but it has struggled since then, because markets won't pay for future earnings. Not UNH's fault.
BUY
Healthcare has historically been a top sector after a yield curve inversion, when people get defensive. UNH dominates in commercial health, Medicare and Medicaid.
Unspecified
Has owned for many years. It is the best play in managed health care and helps payers and payees be more efficient and lower health care costs. Acquires and tucks in acquisitions. Highly innovative and very well managed. Maybe trading a bit on the rich side.
HOLD
An 800-pound gorilla. He'll continue to own it. Controlled costs by putting risk and responsibility on the actual providers of the healthcare services. Incentivizing to control costs at the local level. Short term, you may see costs spike due to pandemic-delayed visits. Medium-long term, you'll be fine.
BUY
It hit a new high today and he's long. It's reasonably valued. He targets at least $550.
HOLD
Likes it. EBV +6, means the stock price is pounding away. Stock could easily go to $650. Model price of $385.81, so it's too expensive by 22%. But any correction back to around $387, he'd buy.
SELL
Very good company, but not as good a stock because of valuation. He owns ANTM instead, trading about 6 multiple points less than UNH, with equally good growth metrics. Higher multiple stocks are selling off. Neither has supply chain issues.
TOP PICK
Clouds of macro risk. This one has consistently had visibility into its business. The most vertically integrated managed care company. Best in class GARP in healthcare. Administer a lot of Medicare and Medicaid. Bipartisan support for a lot of their programs. A consistent performer. Yield is 1.17%. (Analysts’ price target is $530.93)
BUY
Got hurt by Humana's bad report number, but UNH didn't suffer Medicare-related problems like Humana. Rather, UNH reported insanely strong numbers. It's a buying opportunity now. Sees strong upside.
PAST TOP PICK
(A Top Pick Sep 28/20, Up 63%) It continues to do well. It's an insurer, but passed on the actual costs to their health suppliers, as they collect the premiums and maintain fixed costs. This business model has been working well. Is it ethical? One could argue it is, but it's worked for UHN.
DON'T BUY
In the space, he owns ANTM instead, which is half the size. Both have HMOs and PBMs. ANTM is cheaper, and it has as good, if not better, future prospects. 5-year chart shows them running neck-and-neck. Medicare for all is a long way out, given the huge US debt.
BUY
Don't fear a shutdown, but a slowdown due to the new Omicron variant. Best among the health insurers. He also likes Centene. If you can, buy a fractional share, if the price is too high.
DON'T BUY
UNH vs. ANTM He owns ANTM instead, with a valuation of 6-8 multiple points less expensive than UNH. ANTM is well managed, growth rates are very good, and medical cost ratios are inline.
Showing 151 to 165 of 290 entries